Otto T - Search Results

1

Intravesical therapy with pertussis toxin before radical cystectomy in patients with bladder cancer: a Phase I study.

Otto T, Lümmen G, Kälble T, Recker F, Krege S, Bex A, Noll F, Rübben H. Otto T, et al. Urology. 1999 Sep;54(3):458-60. doi: 10.1016/s0090-4295(99)00154-5. Urology. 1999. PMID: 10475354 Clinical Trial.

2

Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial.

Goebell PJ, Otto T, Suhr J, Rübben H. Goebell PJ, et al. Among authors: otto t. J Urol. 2002 Jul;168(1):72-5. J Urol. 2002. PMID: 12050495 Clinical Trial.

3

Influence of pertussis toxin on superficial bladder carcinoma in rats.

Lümmen G, Sperling H, Eisenhardt A, vom Dorp F, Otto T, Rübben H. Lümmen G, et al. Among authors: otto t. Urol Res. 2002 Jul;30(3):199-203. doi: 10.1007/s00240-002-0250-9. Epub 2002 Jun 4. Urol Res. 2002. PMID: 12111185

4

[Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].

Otto T, Kälble T. Otto T, et al. Urologe A. 1994 Nov;33(6):540-6. Urologe A. 1994. PMID: 7817454 Review. German.

5

Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma.

Lümmen G, Goepel M, Möllhoff S, Hinke A, Otto T, Rübben H. Lümmen G, et al. Among authors: otto t. J Urol. 1996 Feb;155(2):455-8. J Urol. 1996. PMID: 8558634 Clinical Trial.

6

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.

Krege S, Giani G, Meyer R, Otto T, Rübben H. Krege S, et al. Among authors: otto t. J Urol. 1996 Sep;156(3):962-6. doi: 10.1016/s0022-5347(01)65673-8. J Urol. 1996. PMID: 8709374 Clinical Trial.

7

Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma.

Krege S, Kalund G, Otto T, Goepel M, Rübben H. Krege S, et al. Among authors: otto t. Eur Urol. 1997;31(4):405-7. doi: 10.1159/000474497. Eur Urol. 1997. PMID: 9187898 Clinical Trial.

8

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study.

Otto T, Bex A, Krege S, Walz PH, Rübben H. Otto T, et al. Cancer. 1997 Aug 1;80(3):465-70. doi: 10.1002/(sici)1097-0142(19970801)80:3<465::aid-cncr14>3.0.co;2-v. Cancer. 1997. PMID: 9241080 Clinical Trial.

9

[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].

Otto T, Krege S, Otto B, Goepel M, Rübben H. Otto T, et al. Among authors: otto b. Urologe A. 1997 May;36(3):243-7. doi: 10.1007/s001200050098. Urologe A. 1997. PMID: 9265345 Clinical Trial. German.

10

Modern concepts in the therapy of urinary tract (kidney, ureter, bladder and prostate) tumours.

Lümmen G, Sperling H, Bex A, Otto T, Rübben H. Lümmen G, et al. Among authors: otto t. Pharmacol Res. 1998 Sep;38(3):151-64. doi: 10.1006/phrs.1998.0356. Pharmacol Res. 1998. PMID: 9782064 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

704 results

Search Page

Filters